Audited financial results (standalone and consolidated) for the quarter and financial year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Decipher Labs Limited reported audited results for FY25 showing a sharp revenue drop — standalone revenue fell to about ₹35.67 lakhs from ₹313.77 lakhs in FY24, an roughly 89% decline. Standalone profit after tax swung to a loss of about ₹10.20 lakhs versus a small profit of ₹2.31 lakhs last year, with EPS turning negative. On a consolidated basis, revenue declined to ₹2,261.25 lakhs from ₹3,587.85 lakhs (about 37% fall), and the consolidated loss widened sharply to ₹508.02 lakhs from ₹167.55 lakhs, driven by weak performance in both pharmaceutical trading and consultancy segments. The consolidated entity also reported a steep negative operating cash flow of ₹981.82 lakhs and its subsidiaries in USA and Bahrain contributed losses of about ₹464 lakhs. The auditor (M/s Ramanatham & Rao) issued an unqualified/unmodified opinion on both standalone and consolidated results.
Shareholders should note a significant deterioration in business performance, with revenue collapsing, losses widening, and negative operating cash flow on a consolidated basis — all signals of stress, though the clean audit opinion and small balance sheet size limit the immediate scope. The stock may remain under pressure until revenue stabilises and the subsidiary losses are contained.